Hylomorph

1. Executive Summary (Confidence: High)

Hylomorph AG, a 2014 ETH Zurich spin-off, has emerged as a disruptive leader in preventive surgical solutions for the implantable device market. The company’s flagship platform, Vesta, addresses the two most critical complications in cardiac implants: fibrotic encapsulation and systemic infection. After graduating from the Wyss Zurich accelerator in 2022, Hylomorph has successfully raised over $18 million in total funding, including an oversubscribed Series B2 round in 2023. With a recent CHF 2. million Innosuisse Swiss Accelerator grant, Hylomorph is currently transitioning to market launch in the US and EU, positioning its bioresorbable drug-eluting envelopes as the future gold standard for cardiac rhythm management (CRM) and neuromodulation.